Advisory Research’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-12,368
Closed -$822K 358
2021
Q3
$822K Sell
12,368
-7,384
-37% -$520K 0.05% 218
2021
Q2
$1.45M Sell
19,752
-2,168
-10% -$143K 0.1% 172
2021
Q1
$1.5M Buy
21,920
+7,929
+57% +$596K 0.11% 161
2020
Q4
$939K Sell
13,991
-6,457
-32% -$350K 0.07% 199
2020
Q3
$1.05M Buy
20,448
+6,180
+43% +$275K 0.1% 170
2020
Q2
$538K Buy
+14,268
New +$488K 0.05% 236

Other funds holding CSTL

Advisory Research's CSTL Position: Q4 2021 in Review

Advisory Research sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 12,368 shares — an estimated $822K sold.

Advisory Research first reported a position in CSTL in Q2 2020 and held it in 6 quarters. The position peaked at $1.5M in Q1 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • Advisory Research reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • Advisory Research sold 12,368 Castle Biosciences shares in Q4 2021, an estimated $822K.
  • Advisory Research first reported a position in Castle Biosciences in Q2 2020 and held it in 6 quarters.
  • Advisory Research's Castle Biosciences position peaked at $1.5M in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Advisory Research's 13F filing for Q4 2021, filed 11 Feb 2022.